ERIS Lifesciences Ltd
ERIS Lifesciences Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q4 FY26 call signalled
1 of 3 strong
The short version
International business: Latin America (LatAm) expected to grow faster in FY27 due to more new product approvals; Africa, Asia, and LatAm remain key geographies with stable mix (~30% Africa, 30% Asia, 25% LatAm). Eris Lifesciences expects DBF revenue growth at 1.3x of covered market growth in FY27 with DBF EBITDA margin steady at ~37%, and higher margin in H2 than H1.
From ERIS Lifesciences Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- International business: Latin America (LatAm) expected to grow faster in FY27 due to more new product approvals; Africa, Asia, and LatAm remain key geographies with stable mix (~30% Africa, 30% Asia, 25% LatAm).
- EU CDMO: No base case revenue expected in FY27; any revenue would be upside; major revenues anticipated from FY28 onwards.
- Domestic Formulations (DBF): Overall DBF growth around 11-12%; insulin and derma therapies already outperforming; cardiovascular (CVD) segment catching up; other oral anti-diabetic (OAD) therapies expected to require more time to catch up.
2 more points management made on revenue & sales performance
Profitability & Margins
See what ERIS Lifesciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- INR 160-180 crores invested in developing a large biotech play (DS facility).
- INR 250 crores invested in Bhopal fill and finish site, which is expected to improve margins and open new markets once operational.
- A map facility set up at Bhopal, considered future-focused but delayed by 1 to 1.5 years.
- Additional plant investment for Swiss Parenterals with commissioning expected in April, doubling current parenteral capacity.
- No major CapEx planned for remediation related to EU GMP inspection; mainly procedural and training-related improvements.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what ERIS Lifesciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
ERIS Lifesciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹757 Cr, net profit ₹279 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What ERIS Lifesciences Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
- Morepen Laboratories Ltd (Q4 FY26)
472 crore, up 22% year-on-year (YoY) from Rs. Key concall takeaways from Morepen Laboratories Ltd's Q4 FY26 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY26)
202.12 Cr., a 2.50% increase quarter-on-quarter (Page 14) . Key concall takeaways from Anuh Pharma Ltd's Q4 FY26 earnings call — and how it ranks against…
- Themis Medicare Ltd (Q4 FY26)
Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Key concall takeaways from Themis Medicare Ltd's Q4 FY26 earnings call…
Frequently Asked Questions
What were ERIS Lifesciences Ltd Q4 FY26 results?
International business: Latin America (LatAm) expected to grow faster in FY27 due to more new product approvals; Africa, Asia, and LatAm remain key geographies with stable mix (~30% Africa, 30% Asia, 25% LatAm). Eris Lifesciences expects DBF revenue growth at 1.3x of covered market growth in FY27 with DBF EBITDA margin steady at ~37%, and higher margin in H2 than H1.
What is ERIS Lifesciences Ltd share price analysis?
ERIS Lifesciences Ltd currently shows a below-average growth signal. The stock trades at a P/E of 29.1 with a market cap of ₹19,057 Cr. Investors should review the full earnings analysis for detailed insights.
Is ERIS Lifesciences Ltd planning capital expenditure?
INR 160-180 crores invested in developing a large biotech play (DS facility).
Keep ERIS Lifesciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.